Literature DB >> 15857992

Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.

Shi-Hua Xiang1, Michael Farzan, Zhihai Si, Navid Madani, Liping Wang, Eric Rosenberg, James Robinson, Joseph Sodroski.   

Abstract

Interaction of the human immunodeficiency virus type 1 (HIV-1) gp120 envelope glycoprotein with the primary receptor, CD4, promotes binding to a chemokine receptor, either CCR5 or CXCR4. The chemokine receptor-binding site on gp120 elicits CD4-induced (CD4i) antibodies in some HIV-1-infected individuals. Like CCR5 itself, the CD4i antibody 412d exhibits a preference for CCR5-using HIV-1 strains and utilizes sulfated tyrosines to achieve binding to gp120. Here, we show that 412d binding requires the gp120 beta19 strand and the base of the V3 loop, elements that are important for the binding of the CCR5 N terminus. Two gp120 residues in the V3 loop base determined 412d preference for CCR5-using HIV-1 strains. A chimeric molecule in which the 412d heavy-chain third complementarity-determining loop sequence replaces the CCR5 N terminus functioned as an efficient second receptor, selectively supporting the entry of CCR5-using HIV-1 strains. Sulfation of N-terminal tyrosines contributed to the function of this chimeric receptor. These results emphasize the close mimicry of the CCR5 N terminus by the gp120-interactive region of a naturally elicited CD4i antibody.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857992      PMCID: PMC1091675          DOI: 10.1128/JVI.79.10.6068-6077.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1.

Authors:  E O Saphire; P W Parren; C F Barbas; D R Burton; I A Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2001-01

2.  Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.

Authors:  P D Kwong; R Wyatt; S Majeed; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Structure       Date:  2000-12-15       Impact factor: 5.006

3.  Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells.

Authors:  Gang Meng; Xiping Wei; Xiaoyun Wu; Marty T Sellers; Julie M Decker; Zina Moldoveanu; Jan M Orenstein; Martin F Graham; John C Kappes; Jiri Mestecky; George M Shaw; Phillip D Smith
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

4.  A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry.

Authors:  M Farzan; N Vasilieva; C E Schnitzler; S Chung; J Robinson; N P Gerard; C Gerard; H Choe; J Sodroski
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

5.  Immune control of HIV-1 after early treatment of acute infection.

Authors:  E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

6.  Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  Shi-Hua Xiang; Peter D Kwong; Rishi Gupta; Carlo D Rizzuto; David J Casper; Richard Wyatt; Liping Wang; Wayne A Hendrickson; Michael L Doyle; Joseph Sodroski
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.

Authors:  E G Cormier; M Persuh; D A Thompson; S W Lin; T P Sakmar; W C Olson; T Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

8.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

9.  Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.

Authors:  S Pontow; L Ratner
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

10.  The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.

Authors:  Emmanuel G Cormier; Tatjana Dragic
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more
  23 in total

1.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

2.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 3.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

4.  Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.

Authors:  Emma T Crooks; Penny L Moore; Douglas Richman; James Robinson; Jeffrey A Crooks; Michael Franti; Norbert Schülke; James M Binley
Journal:  Hum Antibodies       Date:  2005

5.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Authors:  Paul R Gorry; Rebecca L Dunfee; Megan E Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey H Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha J Willey; Paul R Clapham; Steven M Wolinsky; Suzanne M Crowe; Dana Gabuzda
Journal:  Virology       Date:  2007-01-18       Impact factor: 3.616

6.  Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4.

Authors:  Chih-Chin Huang; Son N Lam; Priyamvada Acharya; Min Tang; Shi-Hua Xiang; Syed Shahzad-Ul Hussan; Robyn L Stanfield; James Robinson; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Carole A Bewley; Peter D Kwong
Journal:  Science       Date:  2007-09-28       Impact factor: 47.728

7.  Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Authors:  Milloni B Patel; Noah G Hoffman; Ronald Swanstrom
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

8.  A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.

Authors:  Shi-Hua Xiang; Andrés Finzi; Beatriz Pacheco; Kevin Alexander; Wen Yuan; Carlo Rizzuto; Chih-Chin Huang; Peter D Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  Sulfotyrosine dipeptide: Synthesis and evaluation as HIV-entry inhibitor.

Authors:  Tong Ju; Duoyi Hu; Shi-Hua Xiang; Jiantao Guo
Journal:  Bioorg Chem       Date:  2016-07-25       Impact factor: 5.275

Review 10.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.